John R Fischer

Insurance market ripe for consolidation; Gauge Capital to merge Urology America; reimbursement trends drive PE interest in autism therapy

A roundup of eight deals that sum up why firms like Ares, GTCR and Lightyear Capital are flocking toward the insurance sector; a merger agreement between a Gauge Capital portfolio company and a business recently sold by Apollo; delving into Bourne Partner’s Autism Therapy Market Update that points out a unique trend that may help increase PE involvement in the space.

Cinven, CVC, HCAP pursue diagnostic healthcare companies; Healthcare IT trends drive Oak HC/FT-backed Reveleer’s add-on of Novillus

A five-deal listicle on the diagnostic healthcare provider sector, which has caught the attention of PE firms on both sides of the Atlantic, including Cinven, Clearview Capital, CVC and HCAP Partners; then a look at a healthcare IT platform add-on by an Oak HC/FT-backed company.

PE seeks stakes in healthcare diagnostics sector: 5 deals

Cinven, CVC and HCAP Partners are among the PE firms pursuing investments and add-ons in the diagnostic healthcare provider market.

Dealmakers react to tariff ups and downs; PE firms invest in autism care; women leaders share advice on forging careers in private equity

The unmet needs in autism care are incentivizing PE firms to invest in opportunities to build, grow and sell platforms in the sector.

65 Equity, Arlington, GHO target CDMOs; NMS sells urology platform to General Atlantic

Cost containment, accelerated time-to-market, recurring revenues and strong cash flows are driving PE interest in the CDMO market.

PE taps into CDMO market’s ‘strong growth’: 7 deals

65 Equity Partners, Arlington Capital Partners and Vance Street Capital are among the PE firms targeting investments in the CDMO market.

Autism care supply-demand imbalance is driving PE investments

Calex Partners, Goldman Sachs and Shore Capital are investing in autism care.

Dealmakers face tariff turmoil; Archimed, Nordic Capital, Patricia Industries bet on clinical research tech

Some takeaways from an SS&C Intralinks report on how tariffs may affect deal activity in the second quarter of 2025; a conversation with with Michelle Mantine, partner at law firm Reed Smith, about how the FTC's decision to retain 2023 merger guidelines may affect healthcare investing; the demand for clinical research technologies.

A shift in how healthcare mergers are reviewed is still expected, says Reed Smith's Michelle Mantine

'I think it's going to be easier to do deals in those sectors where there isn't much concentration or consolidation,' she says.

Clinical research tech draws in PE interest: 5 deals

Archimed, Astorg, HIG and TSCP are among the PE firms investing in companies producing clinical research technologies.